Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
View ORCID ProfileRebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, View ORCID ProfileLuis Izquierdo, Eduard Gratacós, Gemma Moncunill, View ORCID ProfileCarlota Dobaño
doi: https://doi.org/10.1101/2021.03.09.21252401
Rebeca Santano
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Diana Barrios
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Fàtima Crispi
bBCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona, Spain
Francesca Crovetto
bBCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona, Spain
Marta Vidal
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Jordi Chi
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Luis Izquierdo
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Eduard Gratacós
bBCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBER-ER, Barcelona, Spain
Gemma Moncunill
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
Carlota Dobaño
aISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Catalonia, Spain
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted March 10, 2021.
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Rebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, Luis Izquierdo, Eduard Gratacós, Gemma Moncunill, Carlota Dobaño
medRxiv 2021.03.09.21252401; doi: https://doi.org/10.1101/2021.03.09.21252401
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Rebeca Santano, Diana Barrios, Fàtima Crispi, Francesca Crovetto, Marta Vidal, Jordi Chi, Luis Izquierdo, Eduard Gratacós, Gemma Moncunill, Carlota Dobaño
medRxiv 2021.03.09.21252401; doi: https://doi.org/10.1101/2021.03.09.21252401
Subject Area
Subject Areas
- Addiction Medicine (333)
- Allergy and Immunology (657)
- Anesthesia (176)
- Cardiovascular Medicine (2557)
- Dermatology (216)
- Emergency Medicine (389)
- Epidemiology (12058)
- Forensic Medicine (10)
- Gastroenterology (738)
- Genetic and Genomic Medicine (3971)
- Geriatric Medicine (375)
- Health Economics (663)
- Health Informatics (2563)
- Health Policy (991)
- Hematology (356)
- HIV/AIDS (822)
- Medical Education (393)
- Medical Ethics (106)
- Nephrology (420)
- Neurology (3737)
- Nursing (206)
- Nutrition (558)
- Oncology (1943)
- Ophthalmology (565)
- Orthopedics (233)
- Otolaryngology (299)
- Pain Medicine (246)
- Palliative Medicine (72)
- Pathology (469)
- Pediatrics (1087)
- Primary Care Research (442)
- Public and Global Health (6403)
- Radiology and Imaging (1352)
- Respiratory Medicine (855)
- Rheumatology (391)
- Sports Medicine (336)
- Surgery (430)
- Toxicology (51)
- Transplantation (184)
- Urology (161)